EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma

Daniela Gabbia iD, Sara De Martin iD

International Journal of Molecular Sciences · 08.02.2023 · 24 (4) · 3441

DOI: 10.3390/ijms24043441 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.02.2023. Verfasst von Daniela Gabbia und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35122 Padova, Italy. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC), the primary hepatic malignancy, represents the second-highest cause of cancer-related death worldwide. Many efforts have been devoted to finding novel biomarkers for predicting both patients’ survival and the outcome of pharmacological treatments, with a particular focus on immunotherapy. In this regard, recent studies have focused on unravelling the role of tumor mutational burden (TMB), i.e., the total number of mutations per coding area of a tumor genome, to ascertain whether it can be considered a reliable biomarker to be used either for the stratification of HCC patients in subgroups with different responsiveness to immunotherapy, or for the prediction of disease progression, particularly in relation to the different HCC etiologies. In this review, we summarize the recent advances on the study of TMB and TMB-related biomarkers in the HCC landscape, focusing on their feasibility as guides for therapy decisions and/or predictors of clinical outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansMutationImmunotherapyBiomarkers, Tumor

Stichwörter der Autor:innen

hepatocellular carcinomaimmune checkpoint inhibitorsimmunotherapyliquid biopsymicrosatellite instabilityneoantigenstumor immune microenvironmenttumor mutational burden

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35122 Padova, Italy.

ORCID-Profile: Daniela Gabbia, Sara De Martin

Zitieren

APA

Gabbia, D., & De Martin, S. (2023). Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 24(4), 3441. https://doi.org/10.3390/ijms24043441

Vancouver

Gabbia D, De Martin S. Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2023;24(4):3441. doi:10.3390/ijms24043441

BibTeX
@article{Gabbia2023,
  author = {Gabbia, Daniela and De Martin, Sara},
  title = {Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {4},
  pages = {3441},
  doi = {10.3390/ijms24043441}
}
Kostenlos starten →